For the roughly 25 million Americans who live with asthma, modern medicine has long offered management but never a cure — treating the storm without addressing the damage it leaves behind. Researchers at Aston University have now identified a molecule that may change that calculus, targeting not the symptoms of asthma but the structural remodeling of the airways that makes the disease a permanent condition. In asthmatic mice, the compound reversed that damage within weeks — a result that, while still far from the clinic, asks a question medicine has rarely been able to pose: what if we could u
Experimental Molecule Shows Promise for Long-Term Asthma Treatment in Mice
targeting the changes in the airway directly
Mark
So this molecule stops asthma from getting worse in mice. Does that mean it could actually reverse the damage that's already happened in a human lung?
Mimi
That's the hope, but it's too early to say. In the mice, the airway walls became thinner and healthier-looking. Whether that translates to actual reversal of damage in humans—damage that may have accumulated over years or decades—is still unknown.
Luke
Right, and we should note: this is mice. The leap from mouse models to human biology is enormous. Plenty of treatments work beautifully in rodents and fail in people.
Mark
Fair point. So what makes this different from what doctors are already doing?
Mimi
Current asthma drugs open the airways during an attack or reduce inflammation. They're symptom management. This targets the root cause—the structural thickening of the airway walls themselves. It's trying to stop the disease from progressing, not just treat the flare-ups.
Luke
Though we should be precise: they've shown it works on the structural changes in mice over two weeks. We don't know if it prevents new remodeling, reverses old remodeling, or both. The paper doesn't say.
Mark
When could people actually get this treatment?
Mimi
Dr. Johnson said human trials are likely years away. They need to figure out dosage, delivery method, safety profile—all the things that take time.
Luke
And funding. She said "given time and funding." That's not a small caveat. This kind of research doesn't move forward without resources.
Mark
So for someone with severe asthma right now, this doesn't help them yet.
Mimi
Not yet. But it's a different kind of approach than anything currently available, which is why it matters.
Le Pouls
- Asthma's true burden isn't just the attacks — it's the slow, permanent thickening of airway walls that current treatments never touch.
- A newly synthesized molecule, LIT-927, blocked the protein CXCL12 that recruits stem cells to remodel airway tissue, halting the damage at its cellular source.
- In asthmatic mice, symptoms faded within a week and had largely resolved by two — with airway walls measurably closer to those of healthy animals.
- For severe asthmatics who don't respond to steroids, this represents the first credible path toward treating the disease's architecture, not just its episodes.
- Researchers must still establish safe dosing, delivery methods, and long-term effects before human trials can begin — a process likely to take several more years.
For the roughly 25 million Americans who live with asthma, modern medicine has long offered management but never a cure — treating the storm without addressing the damage it leaves behind. Researchers at Aston University have now identified a molecule that may change that calculus, targeting not the symptoms of asthma but the structural remodeling of the airways that makes the disease a permanent condition. In asthmatic mice, the compound reversed that damage within weeks — a result that, while still far from the clinic, asks a question medicine has rarely been able to pose: what if we could undo what asthma does to the lungs?
Asthma affects roughly one in thirteen Americans, and for all of modern medicine's sophistication, the treatment playbook has barely changed in decades: inhalers, steroids, drugs to open the airways mid-attack. What none of these address is the underlying structural damage — the way asthma gradually thickens and stiffens airway walls, making each breath a little harder than the last.
Researchers at Aston University traced that damage to a specific cellular event. During inflammation, stem cells called pericytes migrate from blood vessel linings to the airway walls, where they transform into muscle and connective tissue. A protein called CXCL12 appears to be the signal that sets them moving. The team designed a molecule, LIT-927, to block that signal — and introduced it into the nasal passages of asthmatic mice.
The results were difficult to dismiss. Within a week, treated mice showed measurable symptom reduction. By two weeks, the condition had largely resolved, and their airway walls were structurally closer to those of healthy animals. Lead researcher Dr. Jill Johnson noted that for severe asthmatics unresponsive to steroids, a treatment capable of reversing airway remodeling would mark a genuine turning point.
Still, Johnson was deliberate about the distance remaining. Dosage, delivery, duration of effect, and long-term safety all require investigation before any human testing can begin. That work, even under favorable conditions, is likely years away. For now, the finding belongs to the realm of early promise — meaningful, carefully documented, and not yet within reach of the millions who still depend on their inhalers every day.
Asthma remains one of those diseases that modern medicine can manage but not cure. About 25 million Americans live with it—roughly one person in every thirteen. The condition causes the airways to narrow and thicken, making breathing difficult, sometimes dangerously so. For decades, doctors have treated it the same way: with inhalers, steroids, and other drugs designed to open the airways during an attack. But none of these address what's actually happening inside the lungs—the permanent structural damage that asthma causes over time.
A team of researchers at the University of Aston decided to approach the problem differently. They focused on what happens at the cellular level during an asthma attack. When airways become inflamed, stem cells called pericytes—which normally live in the lining of blood vessels—migrate to the airway walls. Once there, they transform into muscle cells and other tissue that thickens the airway walls and makes them less flexible. This remodeling is what causes the characteristic wheezing and shortness of breath that asthmatics know well. The researchers suspected that a protein called CXCL12 was responsible for triggering this migration.
To test their theory, they created a new molecule called LIT-927 and introduced it into the nasal passages of asthmatic mice. The molecule's job was to block CXCL12 and prevent the pericytes from moving to the airways. The results were striking. Within a week, the treated mice showed a reduction in asthma symptoms. By two weeks, the condition had largely disappeared. More importantly, their airways showed significantly less structural damage—the walls were thinner and more closely resembled those of healthy mice.
Dr. Jill Johnson, the lead author of the study published in Respiratory Medicine, acknowledged the significance of the finding. Unlike existing treatments that only manage acute symptoms, this approach targets the underlying damage itself. For severe asthmatics who don't respond to steroids, a treatment that could actually reverse or prevent airway remodeling would represent a genuine breakthrough.
But Johnson was careful to temper expectations. The work remains in its earliest stages. Before the molecule can be tested in humans, researchers need to determine the optimal dosage, the best way to administer it, and how long its effects last. They also need to understand potential side effects and long-term safety. Even if all goes well in the coming years, human trials are likely still several years away. For now, the promise belongs to the mice. For the millions of people reaching for their inhalers every day, the wait continues.
Citations marquantes
By targeting the changes in the airway directly, we hope this approach could eventually offer a more permanent and effective treatment than those already available, particularly for severe asthmatics who don't respond to steroids.— Dr. Jill Johnson, lead author, University of Aston School of Biosciences
Our work is still at an early stage, and further research is needed before we can begin to test this in people.— Dr. Jill Johnson
Envie de l'histoire complète ?
Lire l'original sur IFLScience ↗
Health & Medicine